接触

Pharmaceutical Registration in Indonesia

Bringing a pharmaceutical product to the Indonesian market means navigating one of Southeast Asia's most demanding regulatory environments. PRI manages your pharmaceutical product registration from pre-submission through BPOM approval, and serves as your licensed Local Authorised Representative throughout the process.

Pharmaceutical Product Registration (BPOM / NIE)

We manage end-to-end submission and evaluation follow-up with BPOM, handle clarification responses, and monitor every stage of the evaluation cycle through to Marketing Authorization (Nomor Izin Edar / NIE) approval.

Pre-Registration & Dossier Preparation

We scope your registration pathway through BPOM's Pre-Registration (Pra-Registrasi) stage and prepare your complete pharmaceutical registration dossier, covering all technical, quality, and administrative documents aligned to BPOM and CTD standards.

BA/BE Testing Coordination

Generic pharmaceutical products in Indonesia require a Bioequivalence (BA/BE) study at an Indonesian-accredited facility. We coordinate the full BA/BE process, from study planning and site selection through to report integration into your registration dossier.

Local Authorised Representative (LAR)

Foreign pharmaceutical manufacturers must register through a licensed local entity in Indonesia. PRI serves as your Local Authorised Representative, holding your NIE independently of any distributor arrangement and giving you full commercial flexibility in the Indonesian market.

无缝合规支持

端到端服务

我们负责从许可证申请到产品注册的整个监管流程。.

监管专业知识

我们的团队拥有深厚的知识和丰富的经验，能够应对复杂的监管环境。.

速度与效率

我们行之有效的策略可以加快印尼市场的注册和审批流程。.

定制支持

提供个性化指导和专属支持，确保旅程顺畅无忧。.

End-to-End Pharmaceutical Registration Support in Indonesia

Pharmaceutical registration in Indonesia is governed by BPOM (Badan Pengawas Obat dan Makanan). Every medicine must obtain an official Marketing Authorization (Nomor Izin Edar / NIE) before it can be legally imported, distributed, or sold in the country. The pharmaceutical registration process applies to new drugs, copy drugs, biological products, and biosimilars, each assessed against Indonesian national standards for safety, quality, and efficacy.

For foreign manufacturers who already hold product approvals from EMA, US FDA, TGA Australia, Health Canada, PMDA Japan, or UK MHRA, BPOM offers an accelerated evaluation pathway called Reliance Registration. Under this route, BPOM uses the Full Assessment Report from the reference country to support its review, reducing the evaluation period to 120 working days. This is the most time-efficient entry route for manufacturers already cleared in major global markets, and PRI manages the full submission process including preparation of the required Assessment Report documentation.

PRI brings together pharmaceutical registration consultant expertise and licensed in-country representation under a single engagement. Our team handles pharmaceutical registration dossiers aligned to BPOM standards, supports pharmaceutical company registration requirements for foreign entities, and manages medicine product registration renewals and variation submissions after initial approval. Whether you are entering Indonesia for the first time or expanding an existing product portfolio, we coordinate every phase of the process on your behalf.

预约咨询

市场准入支持

Flexible market entry support for foreign pharmaceutical manufacturers entering the Indonesian market.

Initial Consultation

Free for a 30-minute session with our regulatory experts. We’ll review your product scope and clarify the registration pathway.

分销商选择

我们协助识别和评估符合监管和商业要求的合格本地分销商。.

Export/Import Assistance

We manage customs clearance, import licensing, and regulatory documentation for entering the Indonesian market.

公司注册支持

当您准备在当地设立分支机构时，我们将协助您在印度尼西亚合法注册公司。.

Initial Consultation

Free for a 30-minute session with our regulatory experts. We’ll review your product scope and clarify the registration pathway.

分销商选择

我们协助识别和评估符合监管和商业要求的合格本地分销商。.

Export/Import Assistance

We manage customs clearance, import licensing, and regulatory documentation for entering the Indonesian market.

公司注册支持

当您准备在当地设立分支机构时，我们将协助您在印度尼西亚合法注册公司。.

咨询表

我们的团队随时准备与您探讨您的业务需求，并解答您的任何疑问。请填写我们的咨询表格，我们将在一个工作日内回复。.

Contact Form (CN)
Submit with your company email for quicker response and priority handling.

其他联系我们的方式。.

 常见问题 (FAQ)

Pharmaceutical product registration in Indonesia is the official process through which a product obtains a Marketing Authorization (Nomor Izin Edar/NIE) from BPOM, the national regulatory authority for drugs and food. Every pharmaceutical product, including prescription drugs, over-the-counter medicines, generics, and biological products, must be registered and approved before it can be legally imported, marketed, or distributed in Indonesia. The pharmaceutical registration process evaluates safety, quality, and efficacy against national standards, including Farmakope Indonesia VI.
The pharmaceutical registration process in Indonesia has two primary phases. Phase 1 is Pre-Registration (Pra-Registrasi), where BPOM assesses the application to determine the registration category, evaluation pathway, and required documentation. This stage is typically completed within 40 working days. Phase 2 is Registration and Evaluation (Registrasi), where the full product dossier is submitted alongside the government PNBP fee. For copy drugs, the standard evaluation takes approximately 150 working days. Products eligible for Reliance Registration can be evaluated within 120 working days. BPOM may extend the timeline if additional data or clarification is needed during review.
Pharmaceutical registration dossiers for Indonesia typically include administrative documents such as a Letter of Authorization, Certificate of Free Sale, and GMP certificate, alongside quality documentation aligned to Farmakope Indonesia VI, non-clinical data, clinical data, and product labeling in Bahasa Indonesia. For copy drugs, BA/BE study results are also required. Biological and biosimilar products require additional comparability data. PRI conducts a full documentation gap analysis before submission to confirm dossiers are complete and aligned to BPOM standards.
Yes. Indonesian regulations require the Marketing Authorization (NIE) to be held by a licensed local entity, but foreign manufacturers are not required to establish their own Indonesian company. PRI can serve as your Local Authorised Representative, holding product registrations on your behalf. This gives you full market access in Indonesia while keeping your product approvals independent of any distributor arrangement, and fully transferable if your commercial strategy changes.
Reliance Registration is an accelerated BPOM evaluation pathway where Indonesia uses the assessment results from a recognised reference regulatory authority to support its review decision. Products approved by EMA, US FDA, TGA Australia, Health Canada, PMDA Japan, or UK MHRA qualify for this route. Evaluation is completed within 120 working days rather than the standard timeline. To apply, the registrant must submit the Full Assessment Report from the reference country, including the List of Questions and industry responses. For foreign manufacturers already holding approvals in these markets, Reliance Registration is the most efficient route into Indonesia.
A Bioequivalence (BA/BE) study is a clinical comparison between a copy drug and the reference innovator product, conducted at an Indonesian-accredited testing facility, to confirm they are therapeutically equivalent. BA/BE studies are required for specific generic pharmaceutical products listed in BPOM’s mandatory Bioequivalence testing register under Keputusan BPOM No. 65 Tahun 2022, as well as certain other products subject to BPOM review. The study must be completed before final registration submission. PRI coordinates the full BA/BE process, from study design and site selection through results reporting and dossier integration.
A new drug (obat baru) contains an active ingredient not previously registered in Indonesia, or a registered substance with a new indication, dosage form, strength, or route of administration. Evaluation timelines for new drugs range from 100 to 300 working days depending on the registration route. A copy drug (obat copy/generik) shares the same active ingredient, dosage form, strength, and route of administration as an already-approved product. Copy drugs follow the standard 150-working-day evaluation pathway and typically require BA/BE testing to confirm clinical equivalence to the innovator product.
No. Foreign manufacturers can register and sell products in Indonesia without owning a local manufacturing facility. Pharmaceutical company registration requirements in Indonesia apply to the marketing authorization holder and the distributor, not to the physical location of the manufacturer. Products made abroad are eligible for pharmaceutical registration in Indonesia provided they meet BPOM’s GMP certification requirements and documentation standards. PRI helps foreign manufacturers navigate the full pathway regardless of where the product is manufactured.

具有战略领导力
Hussein H. Mashhour 博士，医学博士

作为我们的首席运营官 (COO)，侯赛因·H·马什胡尔医学博士 (Dr. Hussein H. Mashhour, MD) 在印尼最复杂的监管领域拥有十余年的产品注册和许可实战经验。他的战略指导确保我们的运营流程和客户服务建立在成熟高效的流程之上。选择一位在合规和运营方面都经验丰富的领导者，开启您的旅程，您将获得只有他才能提供的信心和清晰的指导。.

预约免费咨询
探索最新洞察
The Japanese Advantage in Indonesia’s Healthcare Market
Europe Day 2026 Jakarta: What the Evening Revealed About the Compliance Gap European Exporters Cannot Ignore
Complete 2026 Guide for Halal Cosmetic Certification in Indonesia
The Japanese Advantage in Indonesia’s Healthcare Market
Europe Day 2026 Jakarta: What the Evening Revealed About the Compliance Gap European Exporters Cannot Ignore
The Japanese Advantage in Indonesia’s Healthcare Market
查看更多文章

通过电子邮件下载

输入您的电子邮件以将文档发送到您的收件箱。.

文件引导表单